Clinical Trial Update: A Study Evaluates the Safety and Efficacy of WX-0593 in ALK -Positive, or ROS1-positive Non-small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating WX-0593 in ALK-positive or ROS1-positive non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• WX-0593

Snippet

Sponsor: Qilu Pharmaceutical Co., Ltd. | Conditions: Non-small Cell Lung Cancer | Phase 2 | Status: UNKNOWN